<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="pmc-domain-id">1643</journal-id><journal-id journal-id-type="pmc-domain">oncologist</journal-id><journal-id journal-id-type="publisher-id">oncolo</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12265456</article-id><article-id pub-id-type="pmcid-ver">PMC12265456.1</article-id><article-id pub-id-type="pmcaid">12265456</article-id><article-id pub-id-type="pmcaiid">12265456</article-id><article-id pub-id-type="pmid">40577354</article-id><article-id pub-id-type="doi">10.1093/oncolo/oyaf186</article-id><article-id pub-id-type="publisher-id">oyaf186</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Genitourinary Cancer</subject><subj-group subj-group-type="category-toc-heading"><subject>Original Article</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>Oncolo/6</subject></subj-group></article-categories><title-group><article-title>The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1991-6620</contrib-id><name name-style="western"><surname>Sertesen Camoz</surname><given-names initials="E">Elif</given-names></name><aff>
<institution>Department of Medical Oncology, University of Health Science, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bolek</surname><given-names initials="H">Hatice</given-names></name><aff>
<institution>Department of Medical Oncology, Ankara University School of Medicine</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff><aff>
<institution>Ankara University Cancer Research Institute</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuzu</surname><given-names initials="OF">Omer Faruk</given-names></name><aff>
<institution>Department of Medical Oncology, University of Health Science, G&#252;lhane Training and Research Hospital</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sim</surname><given-names initials="S">Saadet</given-names></name><aff>
<institution>Department of Medical Oncology, Ege University School of Medicine</institution>, <addr-line>&#304;zmir</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karaka&#351;</surname><given-names initials="H">Hilal</given-names></name><aff>
<institution>Department of Medical Oncology, Bilkent City Hospital</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sekmek</surname><given-names initials="S">Serhat</given-names></name><aff>
<institution>Department of Medical Oncology, Bilkent City Hospital</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guliyev</surname><given-names initials="M">Murad</given-names></name><aff>
<institution>Department of Medical Oncology, Cerrahpasa School of Medicine</institution>, <addr-line>Istanbul</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akkus</surname><given-names initials="AF">Aysun Fatma</given-names></name><aff>
<institution>Department of Medical Oncology, Trakya University School of Medicine</institution>, <addr-line>Edirne</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Is&#305;k</surname><given-names initials="S">Selver</given-names></name><aff>
<institution>Department of Medical Oncology, Marmara University School of Medicine</institution>, <addr-line>Istanbul</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tural</surname><given-names initials="D">Deniz</given-names></name><aff>
<institution>Department of Medical Oncology, University of Health Science, Bakirkoy Dr. Sadi Konuk Training and Research Hospital</institution>, <addr-line>Istanbul</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3783-7432</contrib-id><name name-style="western"><surname>Arslan</surname><given-names initials="C">Cagatay</given-names></name><aff>
<institution>Medical Point Hospital, Izmir University of Economics</institution>, <addr-line>Izmir</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goksu</surname><given-names initials="SS">Sema Sezgin</given-names></name><aff>
<institution>Department of Medical Oncology, Akdeniz University School of Medicine</institution>, <addr-line>Antalya</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sever</surname><given-names initials="ON">Ozlem Nuray</given-names></name><aff>
<institution>Department of Medical Oncology, Kartal Dr Lutfi Kirdar City Hospital</institution>, <addr-line>Istanbul</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karadurmu&#351;</surname><given-names initials="N">Nuri</given-names></name><aff>
<institution>Department of Medical Oncology, University of Health Science, G&#252;lhane Training and Research Hospital</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karacin</surname><given-names initials="C">Cengiz</given-names></name><aff>
<institution>Department of Medical Oncology, University of Health Science, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ozguroglu</surname><given-names initials="M">Mustafa</given-names></name><aff>
<institution>Department of Medical Oncology, Cerrahpasa School of Medicine</institution>, <addr-line>Istanbul</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sendur</surname><given-names initials="MAN">Mehmet Ali Nahit</given-names></name><aff>
<institution>Department of Medical Oncology, Bilkent City Hospital</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yeked&#252;z</surname><given-names initials="E">Emre</given-names></name><aff>
<institution>Department of Medical Oncology, Ankara University School of Medicine</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff><aff>
<institution>Ankara University Cancer Research Institute</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff><aff>
<institution>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9152-9887</contrib-id><name name-style="western"><surname>&#220;r&#252;n</surname><given-names initials="Y">Y&#252;ksel</given-names></name><xref rid="c1" ref-type="corresp"/><aff>
<institution>Department of Medical Oncology, Ankara University School of Medicine</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff><aff>
<institution>Ankara University Cancer Research Institute</institution>, <addr-line>Ankara</addr-line>, <country country="TR">Turkey</country></aff></contrib></contrib-group><author-notes><corresp id="c1">Corresponding Author: Y&#252;ksel &#220;r&#252;n, Professor Doctor, Ankara University School of Medicine, Department of Medical Oncology, 06620, Ankara, Turkey, Ankara University Cancer Institute, Ankara, Turkey (<email>yukselurun@gmail.com</email>).</corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-07-16"><day>16</day><month>7</month><year>2025</year></pub-date><volume>30</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">492359</issue-id><elocation-id>oyaf186</elocation-id><history><date date-type="received"><day>01</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>16</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-17 00:25:29.227"><day>17</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#8212;for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="oyaf186.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oyaf186.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>The study aims to evaluate the effect of smoking status on treatment results in patients with metastatic renal cell carcinoma (RCC) treated with nivolumab in the second and following lines of therapy.</p></sec><sec id="s2"><title>Materials and Methods</title><p>The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database was used to extract retrospective data from patients with metastatic RCC treated with nivolumab in the second line and beyond. Patients were evaluated according to their smoking status.</p></sec><sec id="s3"><title>Results</title><p>A total of 247 patients were evaluated. The majority of the current smokers were male (93.8%, <italic toggle="yes">P</italic>&#8197;=&#8197;.002). Nivolumab is mainly used in the second-line therapy (84.2%). Median time to treatment failure (TTF) and median overall survival were shorter in patients with currently smoking (10.81 vs. 4.11 months, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001 and 32.33 vs. 16.76 months, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.049, respectively). Multivariate analysis showed that current smoking status was an independent adverse factor on median TTF (HR 2.06 95% confidence interval (CI)&#8197;=&#8197;1.20-3.54, <italic toggle="yes">P</italic>&#8197;=&#8197;.009) and median OS (, HR 2.06, 95% CI&#8197;=&#8197;1.25-3.38, <italic toggle="yes">P</italic>&#8197;=&#8197;.004) in metastatic RCC patients treated with nivolumab in the second line and beyond.</p></sec><sec id="s4"><title>Conclusions</title><p>Current smoking status is an independent adverse prognostic factor for both TTF and OS in patients with metastatic RCC treated with nivolumab in the second line and beyond.</p></sec></abstract><kwd-group><kwd>renal cell carcinoma</kwd><kwd>nivolumab</kwd><kwd>smoking</kwd><kwd>metastatic</kwd></kwd-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text position="float" orientation="portrait"><caption><title>Implications for Practice</title></caption><p>This is an analysis of a multicenter cohort of 247 mRCC patients from the Turkish Oncology Group Kidney Cancer Consortium (TKCC). Current smoking was identified as an independent adverse prognostic factor for both TTF and even after adjusting for confounders. Exploration of the biological mechanisms underlying the negative impact of smoking, including immune system impairment and increased inflammatory markers, is necessary.</p></boxed-text><sec id="s5"><title>Introduction</title><p>Smoking tobacco products is a well-known risk factor for the development of renal cell carcinoma (RCC). Nearly 15% of newly diagnosed RCC patients are active smokers.<sup><xref rid="CIT0001" ref-type="bibr">1</xref></sup> Previous studies showed that smoking status is associated with advanced stage and worse survival outcomes in RCC.<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> In a prospective cohort study where patients were followed for 8.2 years, smoking cessation was associated with a 50% reduction in risk of death and 56% reduction in disease progression, irrespective of tumor stage in RCC patients.<sup><xref rid="CIT0003" ref-type="bibr">3</xref></sup> Smoking tobacco products also have an impact on treatment responses. Active smoking was found to be associated with poor overall survival (OS) in patients with metastatic RCC (mRCC) treated with targeted therapies, such as vascular endothelial growth factor or mammalian target of rapamycin (mTOR) inhibitors.<sup><xref rid="CIT0004" ref-type="bibr">4</xref></sup> The effect of smoking on immunotherapy toxicity and survival has conflicting results according to retrospective series, which include other cancer types as well. Several studies have suggested that never-smokers may derive less benefit from immunotherapy compared to ex- or current smokers, while other studies have shown that never-smokers may have a poorer prognosis or at least a comparable one relative to former or current smokers.<sup><xref rid="CIT0005" ref-type="bibr">5-7</xref></sup> Besides, a retrospective study on metastatic RCC patients treated with immunotherapy-based regimens in the first line concluded that smoking status had no negative impact on OS and time to treatment failure (TTF). Still, former smokers had a higher overall response rate compared to nonsmokers.<sup><xref rid="CIT0008" ref-type="bibr">8</xref></sup></p><p>In this study, we aimed to evaluate the effect of smoking status on treatment results in patients with metastatic RCC treated with nivolumab in the second and following lines of therapy.</p></sec><sec sec-type="materials" id="s6"><title>Materials and methods</title><p>This retrospective study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC). The TKCC database is a multi-institutional retrospective registry comprising data from 13 centers. Although initially collected retrospectively, the database is regularly updated&#8212;both by adding newly diagnosed patients and by revising existing patient records. After each update cycle, data quality control is performed to check for inconsistencies or missing information, and necessary corrections are made. The study included patients with mRCC, aged &#8805;18 years, who received nivolumab as second-line or later therapy between January 2016 and January 2024 .&#160;.&#160;. Patients with unknown smoking status were excluded from the analysis.</p><p>Demographic data (eg, age, gender), nephrectomy status, metastasis sites, nivolumab treatment line, pathological characteristics (eg, histological type, grade, presence of sarcomatoid features), and the start and end dates of nivolumab treatment were extracted from the TKCC database. Ex-smokers were defined as patients who had previously smoked but had quit at least 3 months prior to the initiation of nivolumab treatment. Never-smokers were defined as patients who had never smoked. The primary endpoints of the study were time to TTF is defined as the duration from the initiation of nivolumab therapy to its discontinuation for any reason, and OS is defined as the duration from the start of nivolumab treatment to death from any cause.</p><p>All statistical analyses were performed using SPSS 26.0 for Mac (IBM Corp., Armonk, NY) and R Studio with the survminer, maxstat, and ggsurvplot software packages. We presented continuous variables as medians with interquartile ranges (IQRs) and reported categorical variables as percentages. We used the Chi-square test to compare categorical variables and the Mann&#8211;Whitney <italic toggle="yes">U</italic> test to compare continuous variables. We conducted survival analyses using the Kaplan&#8211;Meier method and compared survival curves using the log-rank test. Multivariate analyses were performed using variables with a <italic toggle="yes">P</italic> value of &#8804;.10 in the univariate analyses. We applied Cox proportional hazards regression models for multivariate analysis of OS and TTF. All reported <italic toggle="yes">P</italic>-values were 2-sided, with a <italic toggle="yes">P</italic>-value&#8197;&lt;&#8197;.05 considered statistically significant.</p></sec><sec id="s7"><title>Results</title><p>A total of 247 patients were included in the study, and 48 of them were current smokers, while 199 of them were ex-smokers or never smokers. Among 247 patients (76.9% male), current smokers were predominantly male (93.8%, <italic toggle="yes">P</italic>&#8197;=&#8197;.002). The median age was 61 years (IQR&#8197;=&#8197;12). Most patients had Eastern Cooperative Oncology Group (ECOG) 0-1 performance score (70.0%), underwent nephrectomy (76.1%), and had clear cell carcinoma (81.8%). Nivolumab was mainly used as second-line therapy (84.2%). The use of nivolumab as a second-line single-agent treatment was due to the reimbursement policies in Turkey. Median time between the diagnosis of the metastatic disease and initiation of the nivolumab treatment was 14.8 months (IQR&#8197;=&#8197;23.57). The baseline characteristics of the current smoker and ex/never-smoker groups were similar except for gender. All patient characteristics are shown in <bold><xref rid="T1" ref-type="table">Table 1</xref></bold>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Variables</th><th align="left" rowspan="1" colspan="1">All patients<break/><italic toggle="yes">N</italic>&#8197;=&#8197;247 (%)</th><th align="left" rowspan="1" colspan="1">Current smoker<break/><italic toggle="yes">N</italic>&#8197;=&#8197;48 (%)</th><th align="left" rowspan="1" colspan="1">Ex or never smoker<break/><italic toggle="yes">N</italic>&#8197;=&#8197;199 (%)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Gender, male</td><td align="left" rowspan="1" colspan="1">190 (76.9)</td><td align="left" rowspan="1" colspan="1">45 (93.8)</td><td align="left" rowspan="1" colspan="1">145 (76.3)</td><td align="left" rowspan="1" colspan="1">
<bold>.002</bold>
</td></tr><tr><td align="left" colspan="2" rowspan="1">Age, years (median, IQR)</td><td align="left" rowspan="1" colspan="1">61 (12)</td><td align="left" rowspan="1" colspan="1">61.5 (11)</td><td align="left" rowspan="1" colspan="1">61 (13)</td><td align="left" rowspan="1" colspan="1">.695</td></tr><tr><td align="left" rowspan="3" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">&lt;65 years</td><td align="left" rowspan="1" colspan="1">156 (63.2)</td><td align="left" rowspan="1" colspan="1">31 (64.6)</td><td align="left" rowspan="1" colspan="1">125 (62.8)</td><td align="left" rowspan="2" colspan="1">.884</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;65 years</td><td align="left" rowspan="1" colspan="1">89 (36)</td><td align="left" rowspan="1" colspan="1">17 (35.4)</td><td align="left" rowspan="1" colspan="1">72 (36.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">105 (42.5)</td><td align="left" rowspan="1" colspan="1">21 (43.8)</td><td align="left" rowspan="1" colspan="1">84 (42.2)</td><td align="left" rowspan="2" colspan="1">.846</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">142 (57.5)</td><td align="left" rowspan="1" colspan="1">27 (56.3)</td><td align="left" rowspan="1" colspan="1">115 (57.8)</td></tr><tr><td align="left" rowspan="3" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">45 (18.2)</td><td align="left" rowspan="1" colspan="1">9 (18.8)</td><td align="left" rowspan="1" colspan="1">36 (18.1)</td><td align="left" rowspan="2" colspan="1">.927</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">201 (81.4)</td><td align="left" rowspan="1" colspan="1">39 (81.3)</td><td align="left" rowspan="1" colspan="1">162 (81.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">1 (0.04)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (0.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">ECOG performance status</td><td align="left" rowspan="1" colspan="1">0-1</td><td align="left" rowspan="1" colspan="1">173 (70)</td><td align="left" rowspan="1" colspan="1">33 (68.8)</td><td align="left" rowspan="1" colspan="1">140 (70.4)</td><td align="left" rowspan="2" colspan="1">.883</td></tr><tr><td align="left" rowspan="1" colspan="1">2-4</td><td align="left" rowspan="1" colspan="1">55 (22.3)</td><td align="left" rowspan="1" colspan="1">10 (20.8)</td><td align="left" rowspan="1" colspan="1">45 (22.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">19 (7.7)</td><td align="left" rowspan="1" colspan="1">5 (10.4)</td><td align="left" rowspan="1" colspan="1">14 (7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Nephrectomy</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">188 (76.1)</td><td align="left" rowspan="1" colspan="1">35 (72.9)</td><td align="left" rowspan="1" colspan="1">153 (76.9)</td><td align="left" rowspan="2" colspan="1">.563</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">59 (23.9)</td><td align="left" rowspan="1" colspan="1">13 (27.1)</td><td align="left" rowspan="1" colspan="1">46 (23.1)</td></tr><tr><td align="left" rowspan="3" colspan="1">Histologic subtype</td><td align="left" rowspan="1" colspan="1">Clear cell</td><td align="left" rowspan="1" colspan="1">202 (81.8)</td><td align="left" rowspan="1" colspan="1">37 (77.1)</td><td align="left" rowspan="1" colspan="1">165 (82.9)</td><td align="left" rowspan="2" colspan="1">.165</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-clear cell</td><td align="left" rowspan="1" colspan="1">27 (10.9)</td><td align="left" rowspan="1" colspan="1">8 (16.7)</td><td align="left" rowspan="1" colspan="1">19 (9.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">18 (7.3)</td><td align="left" rowspan="1" colspan="1">3 (6.3)</td><td align="left" rowspan="1" colspan="1">15 (7.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Presence of sarcomatoid features</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">29 (11.7)</td><td align="left" rowspan="1" colspan="1">4 (8.3)</td><td align="left" rowspan="1" colspan="1">25 (12.6)</td><td align="left" rowspan="2" colspan="1">.519</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">165 (66.8)</td><td align="left" rowspan="1" colspan="1">31 (64.6)</td><td align="left" rowspan="1" colspan="1">134 (67.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">53 (21.5)</td><td align="left" rowspan="1" colspan="1">13 (27.1)</td><td align="left" rowspan="1" colspan="1">40 (20.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">IMDC risk group</td><td align="left" rowspan="1" colspan="1">Favorable</td><td align="left" rowspan="1" colspan="1">11 (4.5)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">11 (5.5)</td><td align="left" rowspan="3" colspan="1">.338</td></tr><tr><td align="left" rowspan="1" colspan="1">Intermediate</td><td align="left" rowspan="1" colspan="1">115 (46.6)</td><td align="left" rowspan="1" colspan="1">17 (35.4)</td><td align="left" rowspan="1" colspan="1">98 (49.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Poor</td><td align="left" rowspan="1" colspan="1">38 (15.4)</td><td align="left" rowspan="1" colspan="1">5 (10.4)</td><td align="left" rowspan="1" colspan="1">33 (16.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">83 (33.6)</td><td align="left" rowspan="1" colspan="1">26 (54.2)</td><td align="left" rowspan="1" colspan="1">57 (28.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">CNS metastasis</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">58 (23.5)</td><td align="left" rowspan="1" colspan="1">10 (20.8)</td><td align="left" rowspan="1" colspan="1">48 (24.1)</td><td align="left" rowspan="2" colspan="1">.507</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">121 (48.9)</td><td align="left" rowspan="1" colspan="1">26 (54.2)</td><td align="left" rowspan="1" colspan="1">95 (47.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">68 (27.5)</td><td align="left" rowspan="1" colspan="1">12 (25)</td><td align="left" rowspan="1" colspan="1">56 (28.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Lung metastasis</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">82 (33.2)</td><td align="left" rowspan="1" colspan="1">16 (33.3)</td><td align="left" rowspan="1" colspan="1">66 (33.2)</td><td align="left" rowspan="2" colspan="1">.816</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">137 (55.5)</td><td align="left" rowspan="1" colspan="1">25 (52.1)</td><td align="left" rowspan="1" colspan="1">112 (56.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">28 (11.3)</td><td align="left" rowspan="1" colspan="1">7 (14.6)</td><td align="left" rowspan="1" colspan="1">21 (10.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Liver metastasis</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">99 (40.1)</td><td align="left" rowspan="1" colspan="1">24 (50)</td><td align="left" rowspan="1" colspan="1">97 (48.7)</td><td align="left" rowspan="2" colspan="1">.482</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">121 (48.9)</td><td align="left" rowspan="1" colspan="1">16 (33.3)</td><td align="left" rowspan="1" colspan="1">83 (41.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">27 (10.9)</td><td align="left" rowspan="1" colspan="1">8 (16.7)</td><td align="left" rowspan="1" colspan="1">19 (9.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Bone metastasis</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">80 (32.4)</td><td align="left" rowspan="1" colspan="1">18 (37.5)</td><td align="left" rowspan="1" colspan="1">62 (31.2)</td><td align="left" rowspan="2" colspan="1">.218</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">139 (56.3)</td><td align="left" rowspan="1" colspan="1">22 (45.8)</td><td align="left" rowspan="1" colspan="1">117 (58.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">28 (11.3)</td><td align="left" rowspan="1" colspan="1">8 (16.7)</td><td align="left" rowspan="1" colspan="1">20 (10.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Nivolumab treatment line</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">208 (84.2)</td><td align="left" rowspan="1" colspan="1">43 (89.6)</td><td align="left" rowspan="1" colspan="1">165 (82.9)</td><td align="left" rowspan="2" colspan="1">.255</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805; 3</td><td align="left" rowspan="1" colspan="1">39 (15.8)</td><td align="left" rowspan="1" colspan="1">5 (10.4)</td><td align="left" rowspan="1" colspan="1">34 (17.1)</td></tr><tr><td align="left" colspan="2" rowspan="1">NLR (median, IQR)</td><td align="left" rowspan="1" colspan="1">3.25 (2.72)</td><td align="left" rowspan="1" colspan="1">3.34 (4.20)</td><td align="left" rowspan="1" colspan="1">3.24 (2.46)</td><td align="left" rowspan="1" colspan="1">.816</td></tr></tbody></table><table-wrap-foot><fn id="T1Fn2"><p>Bold values represent the statistically significant values.</p></fn><fn id="T1Fn1"><p>Abbreviations: CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IQR, interquartile range; NLR, neutrophile lymphocyte ratio.</p></fn></table-wrap-foot></table-wrap><p>Median TTF was longer in the ex/never-smoking group than in the current smoking group (10.81 vs. 4.11 months, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001; <xref rid="F1" ref-type="fig">Figure 1</xref>). Multivariate analysis showed current smoking was an independent risk factor for median TTF (hazard ratio [HR]:2.06, 95% confidence interval (CI)&#8197;=&#8197;1.20-3.54, <italic toggle="yes">P</italic>&#8197;=&#8197;.009), after adjusting for confounding variables (ie, ECOG, nephrectomy, IMDC risk categories, and CNS or bone metastases; <xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>Univariate and multivariate analysis for time to treatment failure.</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2">Variables</th><th align="left" rowspan="2" colspan="1">Median OS<break/>(95%CI)</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" rowspan="1" colspan="1">Multivariate</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">HR (95%CI)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">
<bold>Age</bold>
</td><td align="left" rowspan="1" colspan="1">&lt;65</td><td align="left" rowspan="1" colspan="1">8.38 (6.39-10.36)</td><td align="left" rowspan="2" colspan="1">.459</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;65</td><td align="left" rowspan="1" colspan="1">8.44 (4.12-12.77)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Gender</bold>
</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">6.67 (4.38-8.96)</td><td align="left" rowspan="2" colspan="1">.518</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">9.40 (6.01-12.78)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>ECOG PS</bold>
</td><td align="left" rowspan="1" colspan="1">0-1</td><td align="left" rowspan="1" colspan="1">11.93 (8.68-15.17)</td><td align="left" rowspan="2" colspan="1">
<bold>&lt;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">
<bold>&lt;.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2-3-4</td><td align="left" rowspan="1" colspan="1">3.35 (2.38-4.32)</td><td align="left" rowspan="1" colspan="1">2.93 (1.62-5.29)</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Diabetes mellitus</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">9.40 (5.64-13.15)</td><td align="left" rowspan="2" colspan="1">.459</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">7.06 (4.30-9.82)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Hypertension</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">7.79 (4.41-11.65)</td><td align="left" rowspan="2" colspan="1">.543</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">9.17 (6.05-12.28)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Histological type</bold>
</td><td align="left" rowspan="1" colspan="1">Clear</td><td align="left" rowspan="1" colspan="1">9.17 (6.02-12.31)</td><td align="left" rowspan="2" colspan="1">.221</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Non-clear</td><td align="left" rowspan="1" colspan="1">6.67 (0.43-12.91)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Sarcomatoid feature</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">10.55 (7.36-13.73)</td><td align="left" rowspan="2" colspan="1">.300</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">6.08 (1.80-10.36)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Nephrectomy</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">6.14 (4.30-7.99)</td><td align="left" rowspan="2" colspan="1">
<bold>.038</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">.765</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10.81 (7.32-14.30)</td><td align="left" rowspan="1" colspan="1">0.92 (0.52-1.62)</td></tr><tr><td align="left" rowspan="4" colspan="1">
<bold>IMDC risk group</bold>
</td><td align="left" rowspan="1" colspan="1">Favorable</td><td align="left" rowspan="1" colspan="1">40.11 (NE-NE)</td><td align="left" rowspan="4" colspan="1">
<bold>&lt;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Intermediate</td><td align="left" rowspan="1" colspan="1">13.88 (10.19-17.60)</td><td align="left" rowspan="1" colspan="1">0.89 (0.27-3.00)</td><td align="left" rowspan="1" colspan="1">.856<xref rid="T2Fn1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Poor</td><td align="left" rowspan="1" colspan="1">3.35 (3.15-3.55)</td><td align="left" rowspan="1" colspan="1">2.52 (0.67-9.53)</td><td align="left" rowspan="1" colspan="1">.173<xref rid="T2Fn1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">7.79 (5.25-10.32)</td><td align="left" rowspan="1" colspan="1">1.36 (0.40-4.63)</td><td align="left" rowspan="1" colspan="1">.623<xref rid="T2Fn1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>CNS metastasis</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">9.23 (6.48-11.98)</td><td align="left" rowspan="2" colspan="1">.074</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">.066</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">5.39 (2.43-8.35)</td><td align="left" rowspan="1" colspan="1">1.56 (0.97-2.52)</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Lung metastasis</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">7.09 (4.31-9.88)</td><td align="left" rowspan="2" colspan="1">.744</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">9.66 (4.92-14.40)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Liver metastasis</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">10.55 (5.42-15.67)</td><td align="left" rowspan="2" colspan="1">.295</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">7.49 (4.90-10.08)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Bone metastasis</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">10.48 (4.86-16.09)</td><td align="left" rowspan="2" colspan="1">
<bold>.028</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">
<bold>&lt;.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">6.67 (4.29-9.05)</td><td align="left" rowspan="1" colspan="1">1.67 (1.06-5.29)</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Nivolumab treatment line</bold>
</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">7.79 (5.21-10.369)</td><td align="left" rowspan="2" colspan="1">.334</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805; 3</td><td align="left" rowspan="1" colspan="1">9.66 (5.87-13.46)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Smoking</bold>
</td><td align="left" rowspan="1" colspan="1">Ex/Never</td><td align="left" rowspan="1" colspan="1">10.81 (7.70-3.92)</td><td align="left" rowspan="2" colspan="1">
<bold>&lt;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">
<bold>.009</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Current</td><td align="left" rowspan="1" colspan="1">4.11 (2.60-5.61)</td><td align="left" rowspan="1" colspan="1">2.06 (1.20-3.54)</td></tr></tbody></table><table-wrap-foot><fn id="T2Fn3"><p>Bold values represent the statistically significant values.</p></fn><fn id="T2Fn1"><p>
<sup>*</sup>Compared to IMDC, favorable risk.</p></fn><fn id="T2Fn2"><p>Abbreviations: CI, confidence interval; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NE, not estimated; OS, overall survival; PS, performance status.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p> Kaplan-Meier analysis of time to treatment failure for ex/never smoking and current smoking groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="oyaf186_fig1.jpg"/></fig><p>Median OS was longer in the ex/never-smoking group than in the current smoking group (32.33 vs. 16.76 months, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.049; <xref rid="F2" ref-type="fig">Figure 2</xref>). Multivariate analysis showed current smoking was an independent risk factor for median OS (HR:2.06, 95% CI&#8197;=&#8197;1.25-3.38, <italic toggle="yes">P</italic>&#8197;=&#8197;.004) after adjusting for confounding variables (ie, ECOG, nephrectomy, IMDC risk categories, and CNS or bone metastases; <xref rid="T3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p>Univariate and multivariate analysis for overall survival.</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2">Variables</th><th align="left" rowspan="2" colspan="1">Median OS<break/>(95%CI)</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" rowspan="1" colspan="1">Multivariate</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">HR (95%CI)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">
<bold>Age</bold>
</td><td align="left" rowspan="1" colspan="1">&lt;65</td><td align="left" rowspan="1" colspan="1">35.12 (18.22-52.02)</td><td align="left" rowspan="2" colspan="1">.508</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;65</td><td align="left" rowspan="1" colspan="1">22.60 (11.14-34.06)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Gender</bold>
</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">15.38 (11.88-18.85)</td><td align="left" rowspan="2" colspan="1">
<bold>.031</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">
<bold>.024</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">33.02 (20.99-45.05)</td><td align="left" rowspan="1" colspan="1">0.59 (0.37-0.93)</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>ECOG PS</bold>
</td><td align="left" rowspan="1" colspan="1">0-1</td><td align="left" rowspan="1" colspan="1">48.59 (31.19-65.99)</td><td align="left" rowspan="2" colspan="1">
<bold>&lt;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">
<bold>.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2-3-4</td><td align="left" rowspan="1" colspan="1">12.19 (5.65-18.73)</td><td align="left" rowspan="1" colspan="1">2.26 (1.42-3.59)</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Diabetes mellitus</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">29.57 (20.35-38.78)</td><td align="left" rowspan="2" colspan="1">.769</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">35.12 (16.59-53.64)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Hypertension</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">29.57 (18.74-40.40)</td><td align="left" rowspan="2" colspan="1">.402</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">19.67 (9.30-50.03)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Histological type</bold>
</td><td align="left" rowspan="1" colspan="1">Clear</td><td align="left" rowspan="1" colspan="1">30.32 (15.38-45.26)</td><td align="left" rowspan="2" colspan="1">.074</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">
<bold>.025</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-clear</td><td align="left" rowspan="1" colspan="1">15.57 (8.67-22.48)</td><td align="left" rowspan="1" colspan="1">1.92 (1.09-3.41)</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Sarcomatoid feature</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">29.67 (20.87-38.47)</td><td align="left" rowspan="2" colspan="1">.372</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">30.32 (9.37-51.28)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Nephrectomy</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">16.76 (9.02-24.50)</td><td align="left" rowspan="2" colspan="1">.094</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">.812</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">32.33 (22.31-42.34)</td><td align="left" rowspan="1" colspan="1">0.94 (0.58-1.52)</td></tr><tr><td align="left" rowspan="4" colspan="1">
<bold>IMDC risk group</bold>
</td><td align="left" rowspan="1" colspan="1">Favorable</td><td align="left" rowspan="1" colspan="1">NE (NE-NE)</td><td align="left" rowspan="4" colspan="1">
<bold>&lt;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Intermediate</td><td align="left" rowspan="1" colspan="1">49.54 (34.22-64.87)</td><td align="left" rowspan="1" colspan="1">0.83 (0.25-2.75)</td><td align="left" rowspan="1" colspan="1">.761<xref rid="T3Fn1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Poor</td><td align="left" rowspan="1" colspan="1">4.27 (0.72-7.83)</td><td align="left" rowspan="1" colspan="1">2.66 (0.75-9.43)</td><td align="left" rowspan="1" colspan="1">.128<xref rid="T3Fn1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">26.97 (15.83-38.12)</td><td align="left" rowspan="1" colspan="1">1.24 (0.37-4.24)</td><td align="left" rowspan="1" colspan="1">.726<xref rid="T3Fn1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>CNS metastasis</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">32.33 (19.93-44.73)</td><td align="left" rowspan="2" colspan="1">.331</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">29.67 (10.81-48.53)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Lung metastasis</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">29.67 (18.57-40.77)</td><td align="left" rowspan="2" colspan="1">.744</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">30.32 (7.66-52.99)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Liver metastasis</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">33.01 (21.42-44.62)</td><td align="left" rowspan="2" colspan="1">.426</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">26.97 (10.46-43.48)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Bone metastasis</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">46.00 (29.25-62.75)</td><td align="left" rowspan="2" colspan="1">
<bold>.014</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">
<bold>.010</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">19.91 (8.21-31.61)</td><td align="left" rowspan="1" colspan="1">1.75 (1.14-2.69)</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Nivolumab treatment line</bold>
</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">29.67 (18.20-41.13)</td><td align="left" rowspan="2" colspan="1">.826</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="2" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805; 3</td><td align="left" rowspan="1" colspan="1">30.82 (9.46-52.17)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Smoking</bold>
</td><td align="left" rowspan="1" colspan="1">Ex/Never</td><td align="left" rowspan="1" colspan="1">32.33 (20.22-44.43)</td><td align="left" rowspan="2" colspan="1">
<bold>.049</bold>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="2" colspan="1">
<bold>.004</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Current</td><td align="left" rowspan="1" colspan="1">16.76 (10.39-23.12)</td><td align="left" rowspan="1" colspan="1">2.06 (1.25-3.38)</td></tr></tbody></table><table-wrap-foot><fn id="T3Fn1"><p>
<sup>*</sup>Compared to IMDC, favorable risk.</p></fn><fn id="T3Fn2"><p>Abbreviations: CI, confidence interval; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NE, Not estimated; OS, overall survival; PS, performance status.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Kaplan-Meier analysis of overall survival for ex/never smoking and current smoking groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="oyaf186_fig2.jpg"/></fig></sec><sec id="s8"><title>Discussion</title><p>In this study, our findings indicate that smoking status is an independent adverse prognostic factor for both TTF and OS in patients with mRCC treated with nivolumab. Patients with current smoking status had significantly shorter survival outcomes compared to ex- or never-smokers, even after adjusting for potential confounding variables. These results highlight the negative impact of smoking on treatment efficacy and overall prognosis. Additionally, factors such as poor ECOG performance status, bone metastases, and non-clear cell histology were also associated with worse outcomes, underscoring the importance of patient selection and risk stratification in optimizing nivolumab treatment for metastatic RCC.</p><p>The immune system&#8217;s role in RCC treatment has been well-established since the introduction of interleukin-2 (IL-2) therapy.<sup><xref rid="CIT0009" ref-type="bibr">9</xref></sup> Currently, immune checkpoint inhibitors and their combinations with targeted therapies are the standard first-line treatment for mRCC, tailored to the patient&#8217;s risk group. Smoking is known to impair both innate and adaptive immune responses.<sup><xref rid="CIT0010" ref-type="bibr">10</xref></sup> However, a retrospective study on first-line immunotherapy-based regimens found that former smokers had a higher overall response rate than nonsmokers without translating to OS or TTF benefits.<sup><xref rid="CIT0008" ref-type="bibr">8</xref></sup> Similarly, a post hoc analysis showed that current and former smokers benefited more from the avelumab and axitinib combination compared to sunitinib monotherapy.<sup><xref rid="CIT0011" ref-type="bibr">11</xref></sup> In contrast, our study identified current smoking as an independent adverse prognostic factor for both TTF and OS.</p><p>Studies on immunotherapy efficacy in smoking-related cancers, such as non-small cell lung cancer, suggest that smoking increases tumor mutation burden (TMB)<sup><xref rid="CIT0012" ref-type="bibr">12</xref></sup> and promotes a proinflammatory tumor microenvironment,<sup><xref rid="CIT0013" ref-type="bibr">13</xref></sup> enhancing immunotherapy response.<sup><xref rid="CIT0014" ref-type="bibr">14</xref></sup> However, this does not apply to metastatic RCC, where high TMB does not correlate with immunotherapy outcomes.<sup><xref rid="CIT0015" ref-type="bibr">15</xref>,<xref rid="CIT0016" ref-type="bibr">16</xref></sup> Although TMB was not evaluated in our cohort, patients with a smoking status did not demonstrate improved TTF or OS.</p><p>Inflammation is another factor that attracts the immune system and affects immunotherapies&#8217; treatment responses. A retrospective study examining the effect of pan-immune-inflammation values (PIV) on the survival outcomes of nivolumab treatment for metastatic RCC patients showed that a higher inflammatory score was associated with worse survival outcomes.<sup><xref rid="CIT0017" ref-type="bibr">17</xref></sup> When PIV parameters are considered, smoking also increases neutrophil, lymphocyte, and monocyte counts,<sup><xref rid="CIT0018" ref-type="bibr">18</xref></sup> which indirectly causes an increase in PIV levels. Because of the retrospective nature, we cannot show the direct reason, but both resulted in adverse survival outcomes.</p><p>A prospective study that evaluated smoking cessation after kidney cancer diagnosis showed that it improved all-cause mortality, cancer-specific mortality, and disease progression.<sup><xref rid="CIT0003" ref-type="bibr">3</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref></sup> This effect was evident in both early and metastatic patients. Although the study had a limited number of immunotherapy-treated patients, when our study result is considered, the doctors should suggest that the patient quit smoking.</p><p>ECOG performance status is another factor affecting treatment choices and responses. Patients with ECOG performance scores of 2 or higher are generally excluded from clinical trials. In a meta-analysis, poor performance status was an adverse prognostic factor for metastatic RCC patients treated with tyrosine kinase inhibitors.<sup><xref rid="CIT0020" ref-type="bibr">20</xref></sup> In a multicenter retrospective study, ECOG&#8197;&#8805;&#8197;2 patients treated with immunotherapy-based combinations had worse outcomes, according to the pivotal studies.<sup><xref rid="CIT0021" ref-type="bibr">21</xref></sup> In our research, ECOG performance status was also an independent adverse prognostic factor.</p><p>Bone is the third most common RCC metastatic site and a significant factor for morbidity.<sup><xref rid="CIT0022" ref-type="bibr">22</xref></sup> The presence of bone metastasis is a known adverse prognostic factor for metastatic RCC.<sup><xref rid="CIT0023" ref-type="bibr">23</xref></sup> Some data showed that in site-specific response to nivolumab therapy, as being bone metastasis is one of the worst responses than lung and liver metastasis.<sup><xref rid="CIT0024" ref-type="bibr">24</xref></sup> In our study presence of bone metastasis was an independent prognostic factor for TTF and OS.</p><p>Non-clear cell histology accounts for 20% of RCC patients.<sup><xref rid="CIT0025" ref-type="bibr">25</xref></sup> This group is heterogeneous and underrepresented in clinical trials. Data shaping the treatment strategies generally comes from retrospective studies.<sup><xref rid="CIT0026" ref-type="bibr">26</xref></sup> A study where a similar cohort of patients in Europe showed that patients with non-clear cell histology had worse survival and treatment responses to nivolumab therapy than those with clear cell histology.<sup><xref rid="CIT0027" ref-type="bibr">27</xref></sup> Another analysis of the TKCC and our study has similar results to the European study, in which non-clear cell RCC is an independent prognostic factor.<sup><xref rid="CIT0028" ref-type="bibr">28</xref></sup></p><p>Our study has several limitations, including its retrospective design, which may introduce selection bias, limit causal inferences and missing data (For example, IMDC data were unavailable for 33.6% of patients) Smoking status was based on medical records, lacking detailed information on smoking intensity (pack-years), cessation timing and time between last smoked and diagnosis of cancer. Additionally, TMB and specific immune microenvironment factors were not assessed, which could have provided mechanistic insights. While immunotherapy-based combination regimens are now considered the standard first-line treatment for metastatic RCC, access to these therapies remains limited in many regions due to reimbursement constraints. As a result, vascular endothelial growth factor-targeted tyrosine kinase inhibitors are often used in the first-line setting, and single-agent nivolumab continues to be a widely utilized subsequent-line option in real-world clinical practice. Despite these limitations, the study&#8217;s strengths include its large, real-world cohort of metastatic RCC patients treated with nivolumab in the second line or beyond. It also includes data from multiple cancer centers, enhancing patient representation. The comprehensive analysis of prognostic factors, including smoking status, provides clinically relevant insights and underscores the importance of smoking cessation. Furthermore, the findings align with existing literature while addressing the gap regarding the impact of smoking on immunotherapy outcomes in RCC.</p><p>In conclusion, this study demonstrates that current smoking status is an independent adverse prognostic factor for both TTF and OS in patients with metastatic RCC treated with nivolumab in the second line and beyond. These findings highlight the detrimental impact of smoking on treatment outcomes and underscore the importance of smoking cessation in improving survival among RCC patients. Moreover, other factors such as ECOG performance status, bone metastases, and histological subtypes also play significant roles in determining prognosis.</p><p>Future research should focus on prospective studies to better delineate the biological mechanisms underlying the negative impact of smoking on immunotherapy efficacy. Investigating TMB, immune microenvironment characteristics, and specific causes of death could provide deeper insights into these outcomes. Additionally, evaluating the role of smoking cessation interventions after diagnosis and during treatment could offer practical strategies to enhance survival and quality of life in metastatic RCC patients.</p></sec></body><back><ack id="a1"><title>Acknowledgments</title><p>None.</p></ack><sec id="s9"><title>Author Contributions</title><p>Elif Sertesen Camoz: Writing-original draft, data curation and visualization, Hatice Bolek: Formal analysis, data curation and methodology, Omer Faruk Kuzu: Data curation, Saadet Sim: Data curation, Hilal Karaka&#351;: Data curation, Serhat Sekmek: Data curation, Murad Guliyev: Data curation, Aysun Fatma Akkus: Data curation, Selver Is&#305;k: Data curation, Deniz Tural: Writing &#8211; review &amp; editing, Cagatay Arslan: Writing &#8211; review &amp; editing, Sema Sezgin Goksu: Writing &#8211; review &amp; editing, Ozlem Nuray Sever: Writing &#8211; review &amp; editing, Nuri Karadurmus: Writing &#8211; review &amp; editing, Cengiz Karacin: Writing &#8211; review &amp; editing, Mustafa Ozguroglu: Writing &#8211; review &amp; editing, Mehmet Ali Nahit Sendur: Writing &#8211; review &amp; editing, Emre Yekeduz: Conceptualization, formal analysis, methodology and writing &#8211; review &amp; editing, Y&#252;ksel &#220;r&#252;n: Conceptualization, methodology, supervision, visualization, writing &#8211; review &amp; editing.</p></sec><sec id="s10"><title>Funding</title><p>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></sec><sec sec-type="COI-statement" id="s11"><title>Conflict of Interest Statement</title><p>The authors declare no conflicts of interest in this work.</p></sec><sec sec-type="data-availability" id="s12"><title>Data Availability</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list id="r1"><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gansler</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fedewa</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Dana Flanders</surname><given-names>W</given-names></string-name></person-group>, <etal>et al</etal><article-title>Prevalence of cigarette smoking among patients with different histologic types of kidney cancer</article-title>. <source>Cancer Epidemiol Biomark Prev</source>. <year>2020</year>;<volume>29</volume>:<fpage>1406</fpage>-<lpage>1412</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-0015</pub-id><pub-id pub-id-type="pmcid">PMC9661925</pub-id><pub-id pub-id-type="pmid">32357956</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kroeger</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Klatte</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Birkh&#228;user</surname><given-names>FD</given-names></string-name></person-group>, <etal>et al</etal><article-title>Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival</article-title>. <source>Cancer</source>. <year>2012</year>;<volume>118</volume>:<fpage>1795</fpage>-<lpage>1802</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1002/cncr.26453</pub-id><pub-id pub-id-type="pmid">21997347</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sheikh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mukeriya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zahed</surname><given-names>H</given-names></string-name></person-group>, <etal>et al</etal><article-title>Smoking cessation after diagnosis of kidney cancer is associated with reduced risk of mortality and cancer progression: a prospective cohort study</article-title>. <source>J Clin Oncol</source>. <year>2023</year>;<volume>41</volume>:<fpage>2747</fpage>-<lpage>2755</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1200/JCO.22.02472</pub-id><pub-id pub-id-type="pmid">36989465</pub-id><pub-id pub-id-type="pmcid">PMC10414692</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kroeger</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>De Velasco</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal><article-title>Active smoking is associated with worse prognosis in metastatic renal cell carcinoma patients treated with targeted therapies</article-title>. <source>Clin Genitourin Cancer</source>. <year>2019</year>;<volume>17</volume>:<fpage>65</fpage>-<lpage>71</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.clgc.2018.09.006</pub-id><pub-id pub-id-type="pmid">30341028</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dai</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal><article-title>The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: a systematic review and meta-analysis</article-title>. <source>EClinicalMedicine</source>. <year>2021</year>;<volume>38</volume>:<fpage>100990</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100990</pub-id><pub-id pub-id-type="pmid">34505024</pub-id><pub-id pub-id-type="pmcid">PMC8413256</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Popat</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Scheuer</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal><article-title>Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non-small cell lung cancer</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>:<fpage>e2214046</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.14046</pub-id><pub-id pub-id-type="pmid">35612853</pub-id><pub-id pub-id-type="pmcid">PMC9133943</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rudzi&#324;ska</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Juchaniuk</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Oberda</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy</article-title>. <source>Front Oncol</source>. <year>2024</year>;<volume>14</volume>:<fpage>1459608</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.3389/fonc.2024.1459608</pub-id><pub-id pub-id-type="pmid">39655067</pub-id><pub-id pub-id-type="pmcid">PMC11625667</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saad</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gebrael</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Semaan</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens</article-title>. <source>Oncologist</source>. <year>2024</year>;<volume>29</volume>:<fpage>699</fpage>-<lpage>706</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1093/oncolo/oyae072</pub-id><pub-id pub-id-type="pmid">38630540</pub-id><pub-id pub-id-type="pmcid">PMC11299933</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>N&#233;grier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Escudier</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gomez</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Fran&#231;ais d&#8217;Immunoth&#233;rapie</article-title>. <source>Ann Oncol</source>. <year>2002</year>;<volume>13</volume>:<fpage>1460</fpage>-<lpage>1468</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1093/annonc/mdf257</pub-id><pub-id pub-id-type="pmid">12196373</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Department of Health</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Services</surname><given-names>H.</given-names></string-name></person-group><italic toggle="yes">The Health Consequences of Smoking - 50 Years of Progress: A Report of the Surgeon General.</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/tobacco" ext-link-type="uri">www.cdc.gov/tobacco</ext-link></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Penkov</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Haanen</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Avelumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>:<fpage>1103</fpage>-<lpage>1115</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1056/NEJMoa1816047</pub-id><pub-id pub-id-type="pmid">30779531</pub-id><pub-id pub-id-type="pmcid">PMC6716603</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharpnack</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>TS</given-names></string-name></person-group>, <etal>et al</etal><article-title>Clinical and molecular correlates of tumor mutation burden in non-small cell lung cancer</article-title>. <source>Lung Cancer</source>. <year>2020</year>;<volume>146</volume>:<fpage>36</fpage>-<lpage>41</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.lungcan.2020.05.021</pub-id><pub-id pub-id-type="pmid">32505734</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rakaee</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Busund</surname><given-names>LTR</given-names></string-name>, <string-name name-style="western"><surname>Jamaly</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Prognostic value of macrophage phenotypes in resectable non&#8211;small cell lung cancer assessed by multiplex immunohistochemistry</article-title>. <source>Neoplasia</source><year>2019</year>;<volume>21</volume>:<fpage>282</fpage>-<lpage>293</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.neo.2019.01.005</pub-id><pub-id pub-id-type="pmid">30743162</pub-id><pub-id pub-id-type="pmcid">PMC6369140</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name></person-group>, <etal>et al</etal><article-title>Impact of smoking history on response to immunotherapy in non-small-cell lung cancer: a systematic review and meta-analysis</article-title>. <source>Front Oncol</source>. <year>2021</year>;<volume>11</volume>(<issue>703143</issue>). https://doi.org/<pub-id pub-id-type="doi">10.3389/fonc.2021.703143</pub-id><pub-id pub-id-type="pmcid">PMC8419340</pub-id><pub-id pub-id-type="pmid">34497760</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raimondi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sepe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zattarin</surname><given-names>E</given-names></string-name></person-group>, <etal>et al</etal><article-title>Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer</article-title>. <source>Front Oncol</source>. <year>2020</year>;<volume>10</volume>(<issue>1644</issue>). https://doi.org/<pub-id pub-id-type="doi">10.3389/fonc.2020.01644</pub-id><pub-id pub-id-type="pmcid">PMC7434861</pub-id><pub-id pub-id-type="pmid">32903369</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McDermott</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Huseni</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></string-name></person-group>, <etal>et al</etal><article-title>Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma</article-title>. <source>Nat Med</source>. <year>2018</year>;<volume>24</volume>:<fpage>749</fpage>-<lpage>757</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41591-018-0053-3</pub-id><pub-id pub-id-type="pmid">29867230</pub-id><pub-id pub-id-type="pmcid">PMC6721896</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yeked&#252;z</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tural</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ert&#252;rk</surname><given-names>I</given-names></string-name></person-group>, <etal>et al</etal><article-title>The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study</article-title>. <source>J Cancer Res Clin Oncol</source>. <year>2022</year>;<volume>148</volume>:<fpage>3537</fpage>-<lpage>3546</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1007/s00432-022-04055-5</pub-id><pub-id pub-id-type="pmid">35616728</pub-id><pub-id pub-id-type="pmcid">PMC11800967</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pedersen</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>&#199;olak</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ellervik</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Smoking and increased white and red blood cells: a mendelian randomization approach in the copenhagen general population study</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2019</year>;<volume>39</volume>:<fpage>965</fpage>-<lpage>977</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1161/ATVBAHA.118.312338</pub-id><pub-id pub-id-type="pmid">30866659</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsivian</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Moreira</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Caso</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Mouraviev</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Polascik</surname><given-names>TJ.</given-names></string-name></person-group><article-title>Cigarette smoking is associated with advanced renal cell carcinoma</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>:<fpage>2027</fpage>-<lpage>2031</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1200/JCO.2010.30.9484</pub-id><pub-id pub-id-type="pmid">21502558</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X.</given-names></string-name></person-group><article-title>Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis</article-title>. <source>BMC Cancer</source>. <year>2019</year>;<volume>19</volume>(<issue>168</issue>). https://doi.org/<pub-id pub-id-type="doi">10.1186/s12885-019-5375-0</pub-id><pub-id pub-id-type="pmcid">PMC6385458</pub-id><pub-id pub-id-type="pmid">30795756</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carril-Ajuria</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Colomba</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Romero-Ferreiro</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status</article-title>. <source>Eur J Cancer</source>. <year>2023</year>;<volume>180</volume>:<fpage>21</fpage>-<lpage>29</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.ejca.2022.11.013</pub-id><pub-id pub-id-type="pmid">36527973</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cesana</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cochet</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Filhol</surname><given-names>O.</given-names></string-name></person-group><article-title>New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities</article-title>. <source>Int J Cancer</source>. <year>2024</year>;<volume>156</volume>:<fpage>475</fpage>-<lpage>487</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1002/ijc.35181</pub-id><pub-id pub-id-type="pmid">39306698</pub-id><pub-id pub-id-type="pmcid">PMC11622000</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruatta</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Derosa</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Escudier</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer centre</article-title>. <source>Eur J Cancer</source>. <year>2019</year>;<volume>107</volume>:<fpage>79</fpage>-<lpage>85</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.ejca.2018.10.023</pub-id><pub-id pub-id-type="pmid">30551078</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Negishi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Furubayashi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nakagawa</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal><article-title>Site-specific response to nivolumab in renal cell carcinoma</article-title>. <source>Anticancer Res</source>. <year>2021</year>;<volume>41</volume>:<fpage>1539</fpage>-<lpage>1545</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.21873/anticanres.14913</pub-id><pub-id pub-id-type="pmid">33788747</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gulati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Philip</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Salgia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pal</surname><given-names>SK.</given-names></string-name></person-group><article-title>Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma</article-title>. <source>Cancer Treat Res Commun</source>. <year>2020</year>;<volume>23</volume>:<fpage>100172</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.ctarc.2020.100172</pub-id><pub-id pub-id-type="pmid">32252014</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sepe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ottini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pircher</surname><given-names>CC</given-names></string-name></person-group>, <etal>et al</etal><article-title>Characteristics and treatment challenges of non-clear cell renal cell carcinoma</article-title>. <source>Cancers (Basel)</source>. <year>2021</year>;<volume>13</volume>:<fpage>3807</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.3390/cancers13153807</pub-id><pub-id pub-id-type="pmid">34359706</pub-id><pub-id pub-id-type="pmcid">PMC8345088</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verhaart</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Abu-Ghanem</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mulder</surname><given-names>SF</given-names></string-name></person-group>, <etal>et al</etal><article-title>Real-world data of nivolumab for patients with advanced renal cell carcinoma in the netherlands: an analysis of toxicity, efficacy, and predictive markers</article-title>. <source>Clin Genitourin Cancer</source>. <year>2021</year>;<volume>19</volume>:<fpage>274.e1</fpage>-<lpage>274.e16</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.clgc.2020.10.003</pub-id><pub-id pub-id-type="pmid">33317946</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yeked&#252;z</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ert&#252;rk</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Tural</surname><given-names>D</given-names></string-name></person-group>, <etal>et al</etal><article-title>Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database</article-title>. <source>Future Oncol</source>. <year>2021</year>;<volume>17</volume>:<fpage>4861</fpage>-<lpage>4869</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.2217/fon-2021-0717</pub-id><pub-id pub-id-type="pmid">34726480</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>